Vaxcyte Inc. Common Stock (PCVX)

About PCVX

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigati…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

507

Website

vaxcyte.com

Fundamentals

1-day range

$57.3$58.75

Market cap

$7.73B

P/E (trailing)

—

P/E (forward)

-8.05

EPS (trailing)

$-7.63

Dividend yield

—

Beta

1.21

Avg. volume

1.43M

Forecasts

9 analyst ratings

Vaxcyte Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• PCVX

  Vaxcyte Inc. Common Stock

  $59.83

  ▼ 2.16%
  Market cap $7.73BP/E —
  $29.87$65
• SYRE

  Spyre Therapeutics Inc. Common Stock

  $90.4

  ▼ 3.43%
  Market cap $8.35BP/E —
  $14.51$110.18
• COGT

  Cogent Biosciences Inc. Common Stock

  $34.68

  ▼ 6.50%
  Market cap $6.64BP/E —
  $11.6$43.73
• MIRM

  Mirum Pharmaceuticals Inc. Common Stock

  $97.44

  ▼ 2.32%
  Market cap $6.38BP/E —
  $63.23$130
• ERAS

  Erasca Inc. Common Stock

  $18.03

  ▼ 7.49%
  Market cap $6.11BP/E —
  $1.33$24.28
• BLTE

  Belite Bio Inc American Depositary Shares

  $151.65

  ▼ 3.42%
  Market cap $6.09BP/E —
  $62.18$200
• CYTK

  Cytokinetics Incorporated Common Stock

  $72.17

  ▼ 7.36%
  Market cap $9.51BP/E —
  $35.22$88.31

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

156.84M

Total value held

$8.26B

Institutional holders

330